BACE1 and Alzheimer disease: Furthermore, it has the capacity to lessen the beta-site APP cleaving enzyme 1 (BACE1) protein level and amyloid-β in mouse brains [88], and to limit amyloid-β accumulation, dendritic degeneration, and neuronal death in rats with chronic brain hypoperfusion [89,90], suggesting that it could be a veritable therapeutic agent for AD.